PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Genetics and Pharmacogenomics, Merck & Co., Inc., Kenilworth, New Jersey, United States of America.\', \'Exploratory Science Center, Merck & Co., Inc., Cambridge, Massachusetts, United States of America.\', \'Department of Infectious Diseases and Vaccines, Merck & Co., Inc., West Point, Pennsylvania, United States of America.\', \'Department of Computational and Structural Chemistry, Merck & Co., Inc., West Point, Pennsylvania, United States of America.\', \'Department of Pharmacokinetics, Merck & Co., Inc., West Point, Pennsylvania, United States of America.\', \'Department of Quantitative Biosciences, Merck & Co., Inc., West Point, Pennsylvania, United States of America.\', \'Discovery Biology & Translational Medicine, Merck & Co., Inc., West Point, Pennsylvania, United States of America.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1371/journal.ppat.1009225
?:hasPublicationType
?:journal
  • PLoS pathogens
is ?:pmid of
?:pmid
?:pmid
  • 33596266
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 4.006
?:rankingScore_hIndex
  • 154
?:title
  • SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33596266>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33596266>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all